MX2018005305A - Nuevos antiestrogenos heterociclicos. - Google Patents
Nuevos antiestrogenos heterociclicos.Info
- Publication number
- MX2018005305A MX2018005305A MX2018005305A MX2018005305A MX2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A
- Authority
- MX
- Mexico
- Prior art keywords
- antiestrogens
- novel heterocyclic
- heterocyclic
- novel
- degraders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
La presente invención proporciona nuevos compuestos heterocíclicos como agentes anticancerígenos, especialmente como antagonistas o degradantes 5 del receptor de estrógeno (ER), así como el proceso para su preparación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4058MU2015 | 2015-10-27 | ||
PCT/IN2016/050364 WO2017072792A1 (en) | 2015-10-27 | 2016-10-26 | Novel heterocyclic antiestrogens |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005305A true MX2018005305A (es) | 2019-04-29 |
Family
ID=58629986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005305A MX2018005305A (es) | 2015-10-27 | 2016-10-26 | Nuevos antiestrogenos heterociclicos. |
Country Status (26)
Country | Link |
---|---|
US (2) | US10865199B2 (es) |
EP (2) | EP3368519B1 (es) |
JP (2) | JP6855475B2 (es) |
KR (1) | KR20180088375A (es) |
CN (1) | CN108699021B (es) |
AU (1) | AU2016347679B2 (es) |
BR (1) | BR112018008375B1 (es) |
CA (1) | CA3001958A1 (es) |
DK (1) | DK3368519T3 (es) |
EA (1) | EA034131B1 (es) |
ES (1) | ES2916223T3 (es) |
HR (1) | HRP20220640T1 (es) |
HU (1) | HUE059386T2 (es) |
IL (2) | IL283559B (es) |
LT (1) | LT3368519T (es) |
MX (1) | MX2018005305A (es) |
PH (1) | PH12018500829A1 (es) |
PL (1) | PL3368519T3 (es) |
PT (1) | PT3368519T (es) |
RS (1) | RS63217B1 (es) |
SA (1) | SA518391423B1 (es) |
SG (2) | SG11201803119XA (es) |
SI (1) | SI3368519T1 (es) |
UA (1) | UA122348C2 (es) |
WO (1) | WO2017072792A1 (es) |
ZA (1) | ZA201802615B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL283559B (en) * | 2015-10-27 | 2022-07-01 | Sun Pharma Advanced Res Co Ltd | New heterocyclic anti-estrogens |
US10118910B2 (en) | 2015-12-09 | 2018-11-06 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
JP2020507566A (ja) | 2017-02-10 | 2020-03-12 | ジー1 セラピューティクス, インコーポレイテッド | ベンゾチオフェンエストロゲン受容体モジュレーター |
KR20220046586A (ko) * | 2019-07-22 | 2022-04-14 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 선택적 에스트로겐 수용체 분해제 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
DE69023906T2 (de) | 1990-08-09 | 1996-04-11 | Council Scient Ind Res | Benzopyrane und Verfahren zu deren Herstellung. |
US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
US5389646A (en) * | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
WO1999002512A1 (en) | 1997-07-09 | 1999-01-21 | Novo Nordisk A/S | Dl-2,3-diaryl-2h-1-benzopyrans |
DE10013782A1 (de) * | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
WO2004091488A2 (en) * | 2003-04-14 | 2004-10-28 | Merck & Co., Inc. | Estrogen receptor modulators |
AU2006206446A1 (en) * | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
PL2580210T3 (pl) * | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals, Inc. | Modulatory receptora estrogenowego i ich zastosowania |
BR112014014124A2 (pt) | 2011-12-14 | 2017-08-22 | Seragon Pharmaceutical Inc | Moduladores do receptor de estrogênio fluorados e usos dos mesmos |
CN104169266A (zh) | 2011-12-16 | 2014-11-26 | 奥乐玛药物股份有限公司 | 新的苯并吡喃化合物、其组合物和用途 |
BR112015031903A8 (pt) | 2013-06-19 | 2019-12-31 | Seragon Pharmaceuticals Inc | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
WO2016097073A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
IL283559B (en) * | 2015-10-27 | 2022-07-01 | Sun Pharma Advanced Res Co Ltd | New heterocyclic anti-estrogens |
-
2016
- 2016-10-26 IL IL283559A patent/IL283559B/en unknown
- 2016-10-26 SG SG11201803119XA patent/SG11201803119XA/en unknown
- 2016-10-26 MX MX2018005305A patent/MX2018005305A/es unknown
- 2016-10-26 UA UAA201805396A patent/UA122348C2/uk unknown
- 2016-10-26 PL PL16859220T patent/PL3368519T3/pl unknown
- 2016-10-26 ES ES16859220T patent/ES2916223T3/es active Active
- 2016-10-26 EA EA201890981A patent/EA034131B1/ru unknown
- 2016-10-26 CA CA3001958A patent/CA3001958A1/en active Pending
- 2016-10-26 AU AU2016347679A patent/AU2016347679B2/en active Active
- 2016-10-26 BR BR112018008375-5A patent/BR112018008375B1/pt active IP Right Grant
- 2016-10-26 DK DK16859220.2T patent/DK3368519T3/da active
- 2016-10-26 EP EP16859220.2A patent/EP3368519B1/en active Active
- 2016-10-26 JP JP2018521529A patent/JP6855475B2/ja active Active
- 2016-10-26 CN CN201680072702.8A patent/CN108699021B/zh active Active
- 2016-10-26 RS RS20220454A patent/RS63217B1/sr unknown
- 2016-10-26 SI SI201631534T patent/SI3368519T1/sl unknown
- 2016-10-26 US US15/770,824 patent/US10865199B2/en active Active
- 2016-10-26 HR HRP20220640TT patent/HRP20220640T1/hr unknown
- 2016-10-26 EP EP22164031.1A patent/EP4043438A1/en active Pending
- 2016-10-26 HU HUE16859220A patent/HUE059386T2/hu unknown
- 2016-10-26 KR KR1020187012256A patent/KR20180088375A/ko not_active Application Discontinuation
- 2016-10-26 PT PT168592202T patent/PT3368519T/pt unknown
- 2016-10-26 WO PCT/IN2016/050364 patent/WO2017072792A1/en active Application Filing
- 2016-10-26 SG SG10201913001SA patent/SG10201913001SA/en unknown
- 2016-10-26 LT LTEPPCT/IN2016/050364T patent/LT3368519T/lt unknown
-
2018
- 2018-04-18 PH PH12018500829A patent/PH12018500829A1/en unknown
- 2018-04-19 ZA ZA2018/02615A patent/ZA201802615B/en unknown
- 2018-04-24 SA SA518391423A patent/SA518391423B1/ar unknown
- 2018-04-26 IL IL258949A patent/IL258949B/en active IP Right Grant
-
2020
- 2020-10-28 US US17/082,488 patent/US11465990B2/en active Active
-
2021
- 2021-03-17 JP JP2021043019A patent/JP7052111B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3577110T1 (sl) | 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a | |
PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
PH12018500829A1 (en) | Novel heterocyclic antiestrogens | |
PH12018502535B1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
PH12017500660A1 (en) | Novel compositions, uses and methods for making them | |
MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
PH12016502142A1 (en) | Anti-ptk7 antibody-drug conjugates | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
PH12016502607A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
SG10201902326XA (en) | Mk2 inhibitors and uses thereof | |
NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
PH12018502274A1 (en) | Semaglutide in cardiovascular conditions | |
AU2016361427A8 (en) | Platinum anticancer agents | |
MX2017011116A (es) | Composiciones novedosas, usos y metodos para hacerlas. | |
PH12018501844A1 (en) | Liraglutide in cardiovascular conditions | |
MX2017010526A (es) | Mezclas de aceite, procesos para la preparacion de estas y su uso en formulas. | |
SI3625221T1 (sl) | Derivati 3-metil-pirolidin-2,5-diona uporabni kot antagonisti CGRP receptorja | |
MX2017000520A (es) | Derivados de azaspiro(4.5)decano sustituido. | |
MY174200A (en) | Process for reducing the chlorine content of organotetraphosphites | |
MX2017000519A (es) | Derivados de azaspiro(4.5)decano sustituido. | |
IN2014MU00001A (es) | ||
IN2014MU00599A (es) | ||
MX2017010899A (es) | Proceso para la preparacion de triazoles. | |
MX2017011391A (es) | Procedimiento para la preparacion de clorhidrato de piperidina-4-carbotioamida. | |
MX2017011388A (es) | Proceso para la preparacion de derivados de fenilisoxazolina sustituida. |